Compare AVTX & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVTX | OPFI |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 288.7M |
| IPO Year | 2015 | N/A |
| Metric | AVTX | OPFI |
|---|---|---|
| Price | $19.09 | $10.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $32.29 | $13.50 |
| AVG Volume (30 Days) | 298.2K | ★ 511.5K |
| Earning Date | 11-06-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 2.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $192,000.00 | ★ $335,423,000.00 |
| Revenue This Year | N/A | $120.32 |
| Revenue Next Year | N/A | $10.85 |
| P/E Ratio | ★ N/A | $78.29 |
| Revenue Growth | N/A | ★ 28.69 |
| 52 Week Low | $3.39 | $6.81 |
| 52 Week High | $20.72 | $17.73 |
| Indicator | AVTX | OPFI |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 57.14 |
| Support Level | $17.18 | $10.56 |
| Resistance Level | $20.20 | $11.35 |
| Average True Range (ATR) | 1.72 | 0.41 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 69.94 | 63.74 |
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.